Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Shandong Pharmaceutical Glass Co's 3-Year RORE % for the quarter that ended in Mar. 2026 was -12.02%.
SHSE:600529's 3-Year RORE % is ranked worse than 62.27% of 379
companies
in the Packaging & Containers industry
Industry Median: -0.38
vs SHSE:600529: -12.02
Shandong Pharmaceutical Glass Co (SHSE:600529) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Shandong Pharmaceutical Glass Co 3-Year RORE % Related Terms
Shandong Pharmaceutical Glass Co 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Pharmaceutical Glass Co 3-Year RORE % Chart
SHSE:600529 vs SW, PKG, IP: 3-Year RORE % Comparison
For the Packaging & Containers subindustry, Shandong Pharmaceutical Glass Co's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Pharmaceutical Glass Co 3-Year RORE % vs Packaging & Containers Industry
For the Packaging & Containers industry and Consumer Cyclical sector, Shandong Pharmaceutical Glass Co's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Shandong Pharmaceutical Glass Co's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Shandong Pharmaceutical Glass Co (SHSE:600529) has a 3-Year RORE % of -12.02 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Shandong Pharmaceutical Glass Co and its competitors. According to the industry distribution chart, Shandong Pharmaceutical Glass Co ranks #236 out of 379 companies in the Packaging & Containers industry, placing it in the top 62.3%.
Is Shandong Pharmaceutical Glass Co's 3-Year RORE % too high?
Shandong Pharmaceutical Glass Co's current 3-Year RORE % is -12.02. Based on the distribution chart, Shandong Pharmaceutical Glass Co ranks #236 out of 379 companies in the Packaging & Containers industry, which is below the industry midpoint. Overall, Shandong Pharmaceutical Glass Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Pharmaceutical Glass Co's 3-Year RORE % compare to SW and PKG?
According to the Packaging & Containers industry distribution chart, Shandong Pharmaceutical Glass Co ranks #236 out of 379 companies for 3-Year RORE %. This places Shandong Pharmaceutical Glass Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Packaging & Containers company?
A good 3-Year RORE % depends on the Packaging & Containers industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Shandong Pharmaceutical Glass Co and its competitors. Shandong Pharmaceutical Glass Co's current 3-Year RORE % is -12.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Pharmaceutical Glass Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Pharmaceutical Glass Co (SHSE:600529) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥24.53, compared to a current price of ¥19.32 — trading 21.2% below its estimated fair value. The current 3-Year RORE % is -12.02. Shandong Pharmaceutical Glass Co's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Shandong Pharmaceutical Glass Co (SHSE:600529), the current 3-Year RORE % is -12.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Pharmaceutical Glass Co (SHSE:600529) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Pharmaceutical Glass Co stock appears to be undervalued.
The current stock price of ¥19.32 is trading 21.2% below its estimated GF Value™ of ¥24.53.
GuruFocus considers Shandong Pharmaceutical Glass Co to be Modestly Undervalued.
Key valuation signals for SHSE:600529:
3-Year RORE %: -12.02
GF Value™: ¥24.53 vs. price of ¥19.32 (21.2% below fair value)
No single metric tells the full story. See the SHSE:600529 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Pharmaceutical Glass Co Ltd is a pharmaceutical glass packaging product company. Its pharmaceutical glass packaging products and butyl rubber series products which service object of pharmaceutical, food, daily necessities industries. The products include for moulded injection vial for antibiotics series, tubular glass vial series, amber glass bottle series, neutral borosilicate glass bottle series, infusion bottle series, cosmetic bottles series, food bottles series, butyl rubber stopper series, prefillable syringes series, and aluminum-plastic cap series.
90GF Score
Get the complete analysis for SHSE:600529
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600529 has been successfully added to your 
